YS Biopharma Co. Ltd. (YS)
NASDAQ: YS
· Real-Time Price · USD
1.02
0.09 (9.68%)
At close: May 24, 2024, 10:00 PM
Company Description
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.
It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles.
It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines.
The company was founded in 2002 and is based in Beijing, China.
YS Biopharma Co. Ltd.
| Country | CN |
| IPO Date | Aug 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 773 |
| CEO | Hui Shao |
Contact Details
Address: Building No. 2 Beijing, CN | |
| Website | https://www.yishengbio.com |
Stock Details
| Ticker Symbol | YS |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001946399 |
| CUSIP Number | n/a |
| ISIN Number | KYG9845F1090 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dave Chenn | Co-Chief Executive Officer |
| Dr. Hui Shao C.F.A., M.B.A., Ph.D. | Co-Chief Executive Officer, President, Chief Business Officer & Executive Director |
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research |
| Dr. Zenaida Reynoso Mojares M.D. | Chief Medical Officer |
| Gang Li | Head of Marketing & Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 31, 2025 | 6-K | Filing |
| Jul 31, 2025 | 20-F | Filing |
| Jul 22, 2025 | SCHEDULE 13D | Filing |
| Jul 15, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Jul 15, 2025 | 6-K | Filing |
| Jul 08, 2025 | 6-K | Filing |
| May 12, 2025 | 6-K | Filing |
| May 06, 2025 | 6-K | Filing |
| Mar 25, 2025 | 6-K | Filing |
| Mar 14, 2025 | S-8 POS | Filing |